Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis

  • Review Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

The objective was to compare the clinical efficacy and safety of pharmacological interventions for interstitial cystitis and bladder pain syndrome (IC/BPS) with direct and indirect evidence from randomized trials.

Methods

We searched PubMed, the Cochrane library, and EMBASE for randomized controlled trials (RCTs) that assessed the pharmacological therapies for IC/BPS. Primary efficacy outcomes included ICSI (O’Leary Sant Interstitial Cystitis Symptom Index), ICPI (O’Leary Sant Interstitial Cystitis Problem Index), 24-h micturition frequency, visual analog scale (VAS), and Likert score for pain. Safety outcomes are total adverse events (AEs, intravesical instillation, and others), gastrointestinal symptoms, headache, pain, and urinary symptoms. A systematic review and Bayesian network meta-analysis were performed.

Results

A total of 23 RCTs with 1,871 participants were identified. The ICSI was significantly reduced in the amitriptyline group (MD = −4.9, 95% CI: −9.0 to −0.76), the cyclosporine A group (MD = -7.9, 95% CI: −13.0 to −3.0) and the certolizumab pegol group (MD = −3.6, 95% CI:−6.5 to −0.63) compared with placebo group. Moreover, for ICPI, cyclosporine A showed superior benefit compared to placebo (MD = −7.6, 95% CI: −13 to −2.3). VAS score improved significantly in cyclosporine A group than pentosan polysulfate sodium (MD = 3.09, 95% CI: 0.13 to 6.07). None of the agents revealed a significant alleviation of 24-h micturition frequency. In terms of safety outcomes, the incidence rate on urinary symptoms for botulinum toxin A was the only variate higher than chondroitin sulfate (MD = −2.02, 95% CI: −4.99 to 0.66) and placebo (MD = −1.60, 95% CI:−3.83 to 0.17). No significant difference was found among the other treatments.

Conclusions

Cyclosporine A might be superior to other pharmacological treatments in efficacy. Amitriptyline and certolizumab pegol were capable of lowering the ICSI as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28(4):274–86. https://doi.org/10.1002/nau.20687.

    Article  PubMed  Google Scholar 

  2. Patnaik SS, Laganà AS, Vitale SG, Butticè S, Noventa M, Gizzo S, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet. 2017;295(6):1341–59. https://doi.org/10.1007/s00404-017-4364-2.

    Article  CAS  PubMed  Google Scholar 

  3. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53. https://doi.org/10.1016/j.juro.2015.01.086.

    Article  PubMed  Google Scholar 

  4. Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018;122(5):729–43. https://doi.org/10.1111/bju.14399.

    Article  PubMed  Google Scholar 

  5. Gülpınar Ö, Esen B, Kayış A, Gökçe Mİ, Süer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37(1):257–62. https://doi.org/10.1002/nau.23284.

    Article  CAS  PubMed  Google Scholar 

  6. Parsons CL, Zupkas P, Proctor J, Koziol J, Franklin A, Giesing D, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–12. https://doi.org/10.1111/j.1743-6109.2011.02542.x.

    Article  CAS  PubMed  Google Scholar 

  7. Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33. https://doi.org/10.1016/j.urology.2015.01.021.

    Article  PubMed  Google Scholar 

  8. Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al. A randomized controlled trial of intravesical bacillus Calmette–Guerin for treatment refractory interstitial cystitis. J Urol. 2005;173(4):1186–91. https://doi.org/10.1097/01.ju.0000152337.82806.e8.

    Article  PubMed  Google Scholar 

  9. Chuang Y-C, Kuo H-C. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis/bladder pain syndrome. J Urol. 2017;198(2):376–82. https://doi.org/10.1016/j.juro.2017.02.021.

    Article  CAS  PubMed  Google Scholar 

  10. Pinto RA, Costa D, Morgado A, Pereira P, Charrua A, Silva J, et al. Intratrigonal OnabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J Urol. 2018;199(4):998-1003. https://doi.org/10.1016/j.juro.2017.10.018.

    Article  CAS  PubMed  Google Scholar 

  11. Kuo Y-C, Kuo H-C. O'Leary–Sant symptom index predicts the treatment outcome for OnabotulinumtoxinA injections for refractory interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(8):2860–71. https://doi.org/10.3390/toxins7082860.

    Article  CAS  Google Scholar 

  12. Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8. https://doi.org/10.1016/j.juro.2009.12.106.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Al-Zahrani AA, Gajewski JB. Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome. Can Urol Assoc J. 2011;5(2):113–8. https://doi.org/10.5489/cuaj.10095.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ogawa T, Ishizuka O, Ueda T, Tyagi P, Chancellor MB, Yoshimura N. Pharmacological management of interstitial cystitis/bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. Expert Rev Clin Pharmacol. 2018;11(5):495–505. https://doi.org/10.1080/17512433.2018.1457435.

    Article  CAS  PubMed  Google Scholar 

  15. Wyndaele JJJ, Riedl C, Taneja R, Lovász S, Ueda T, Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019;38(2):535–44. https://doi.org/10.1002/nau.23900.

    Article  PubMed  Google Scholar 

  16. Wammack R, Remzi M, Seitz C, Djavan B, Marberger M. Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur Urol. 2002;41(6):596–600; discussion 601. https://doi.org/10.1016/s0302-2838(02)00174-4.

    Article  CAS  PubMed  Google Scholar 

  17. Lam KH, Yao G, Jin R. Diverse binding modes, same goal: the receptor recognition mechanism of botulinum neurotoxin. Prog Biophys Mol Biol. 2015;117(2–3):225–31. https://doi.org/10.1016/j.pbiomolbio.2015.02.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhang W, Deng X, Liu C, Wang X. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–25. https://doi.org/10.1007/s00192-016-3079-4.

    Article  PubMed  Google Scholar 

  19. Matsuoka PK, Haddad JM, Pacetta AM, Baracat EC. Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J. 2012;23(9):1147–53. https://doi.org/10.1007/s00192-012-1686-2.

    Article  CAS  PubMed  Google Scholar 

  20. Guo C, Yang B, Gu W, Peng B, Xia S, Yang F, et al. Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta-analysis. PLoS One. 2013;8(12):e82591. https://doi.org/10.1371/journal.pone.0082591.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Biol. 2014;175:30–7. https://doi.org/10.1016/j.ejogrb.2013.12.041.

    Article  CAS  PubMed  Google Scholar 

  22. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L Jr. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health interstitial cystitis database study. J Urol. 1999;161(2):553–7. https://doi.org/10.1016/s0022-5347(01)61948-7.

    Article  CAS  PubMed  Google Scholar 

  23. O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58–63. https://doi.org/10.1016/s0090-4295(99)80333-1.

    Article  CAS  PubMed  Google Scholar 

  24. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J. Network meta-analysis using R: a review of currently available automated packages. PLoS One. 2014;9(12):e115065. https://doi.org/10.1371/journal.pone.0115065.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172(2):533–6. https://doi.org/10.1097/01.ju.0000132388.54703.4d.

    Article  PubMed  Google Scholar 

  27. Chen H, Wang F, Chen W, Ye X, Zhou Q, Shao F, et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial—treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. Urology. 2014;84(1):51–6. https://doi.org/10.1016/j.urology.2014.02.050.

    Article  PubMed  Google Scholar 

  28. Bosch PC. A randomized, double-blind, placebo-controlled trial of Certolizumab Pegol in women with refractory interstitial cystitis/bladder pain syndrome. Eur Urol. 2018;74(5):623–30. https://doi.org/10.1016/j.eururo.2018.07.026.

    Article  CAS  PubMed  Google Scholar 

  29. Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191(1):77–82. https://doi.org/10.1016/j.juro.2013.06.038.

    Article  CAS  PubMed  Google Scholar 

  30. Wang H, Russell LJ, Kelly KM, Wang S, Thipphawong J. Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. BMC Urol. 2017;17(1):2. https://doi.org/10.1186/s12894-016-0193-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–21. https://doi.org/10.1016/j.juro.2010.12.088.

    Article  CAS  PubMed  Google Scholar 

  32. Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. A phase II study of the efficacy and safety of the novel Oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis/bladder pain syndrome. J Urol. 2016;196(3):747–54. https://doi.org/10.1016/j.juro.2016.03.003.

    Article  CAS  PubMed  Google Scholar 

  33. Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53. https://doi.org/10.1016/j.eururo.2011.07.069.

    Article  PubMed  Google Scholar 

  34. Cervigni M, Sommariva M, Tenaglia R, Porru D, Ostardo E, Giammo A, et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(4):1178–86. https://doi.org/10.1002/nau.23091.

    Article  CAS  PubMed  Google Scholar 

  35. Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: A randomized double-blind clinical trial. J Urol. 2008;179(1):177–85.

  36. Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174(6):2235–8. https://doi.org/10.1097/01.ju.0000181808.45786.84.

    Article  CAS  PubMed  Google Scholar 

  37. Nickel JC, Herschorn S, Whitmore KE, Forrest JB, Hu P, Friedman AJ, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62. https://doi.org/10.1016/j.juro.2014.09.036.

    Article  CAS  PubMed  Google Scholar 

  38. Gülpınar Ö, Esen B, Kayış A, Gökçe Mİ, Süer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;37(1):257–62.

  39. El-Bahnasy AE, Farahat YA, El-Bendary M, et al. A randomized controlled trail of bacillus calmette-guerin and botulinum toxin-A for the treatment of refractory interstitial cystitis[J]. Urotoday Int J. 2008;02(1).

  40. Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MJ. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–8.

  41. Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E. A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2014;25(5):593–9.

  42. Nickel JC, Egerdie RB, Steinhoff G, Palmer B, Hanno P. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology. 2010;76(4):804–9.

  43. Irani D, Heidari M, Khezri AA. The efficacy and safety of intravesical Bacillus-Calmette-Guerin in the treatment of female patients with interstitial cystitis: a double-blinded prospective placebo controlled study. Urol J. 2004 Spring;1(2):90–3.

  44. Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, et al. Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus calmette-guerin or placebo. J Urol. 2008;179(2):552–5.

  45. Özkıdık M. Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome. Cent European J Urol. 2019;72:270–5. https://doi.org/10.5173/ceju.2019.0007.

  46. Lin YH, Chiang BJ, Liao CH (2020) Mechanism of action of botulinum toxin a in treatment of functional urological disorders. Toxins (Basel) 12 (2):129. https://doi.org/10.3390/toxins12020129.

    Article  CAS  Google Scholar 

  47. Kocatürk H, Atasoy N, Bedir F, Altay MS, Demirdöğen ŞO, Koç E, et al. Questionnaire-guided evaluation of the effectiveness of long-term intravesical 0.2% chondroitin sulfate therapy in interstitial cystitis. Int Urogynecol J. 2020. https://doi.org/10.1007/s00192-020-04245-0.

    Article  PubMed  Google Scholar 

  48. Scarneciu I, Bungau S, Lupu AM, Scarneciu CC, Bratu OG, Martha O, et al. Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS/IC and uncomplicated recurrent urinary tract infections—long-term results of a multicenter study. Eur J Pharm Sci. 2019;139:105067. https://doi.org/10.1016/j.ejps.2019.105067.

    Article  CAS  PubMed  Google Scholar 

  49. Tirumuru S, Al-Kurdi D, Latthe P. Intravesical botulinum toxin a injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J. 2010;21(10):1285–300. https://doi.org/10.1007/s00192-010-1162-9.

    Article  PubMed  Google Scholar 

  50. Crescenze IM, Tucky B, Li J, Moore C, Shoskes DA. Efficacy, side effects, and monitoring of Oral cyclosporine in interstitial cystitis-bladder pain syndrome. Urology. 2017;107:49–54. https://doi.org/10.1016/j.urology.2017.05.016.

    Article  PubMed  Google Scholar 

  51. Wang Z, Zhang L. Treatment effect of cyclosporine a in patients with painful bladder syndrome/interstitial cystitis: a systematic review. Exp Ther Med. 2016;12(1):445–50. https://doi.org/10.3892/etm.2016.3301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Forrest JB, Payne CK, Erickson DR. Cyclosporine a for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186–91. https://doi.org/10.1016/j.juro.2012.06.023.

    Article  CAS  PubMed  Google Scholar 

  53. Giusto LL, Zahner PM, Shoskes DA. An evaluation of the pharmacotherapy for interstitial cystitis. Expert Opin Pharmacother. 2018;19(10):1097–108. https://doi.org/10.1080/14656566.2018.1491968.

    Article  CAS  PubMed  Google Scholar 

  54. Dijkmans B, Gerards A. Cyclosporin in rheumatoid arthritis: monitoring for adverse effects and clinically significant drug interactions. BioDrugs. 1998;10(6):437–45. https://doi.org/10.2165/00063030-199810060-00002.

    Article  CAS  PubMed  Google Scholar 

  55. Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):19–27. https://doi.org/10.1111/j.1468-3083.2011.03992.x.

    Article  CAS  PubMed  Google Scholar 

  56. Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171(6 Pt 1):2138–41. https://doi.org/10.1097/01.ju.0000125139.91203.7a.

    Article  CAS  PubMed  Google Scholar 

  57. Ehrén I, Hallén Grufman K, Vrba M, Sundelin R, Lafolie P. Nitric oxide as a marker for evaluation of treatment effect of cyclosporine a in patients with bladder pain syndrome/interstitial cystitis type 3C. Scand J Urol. 2013;47(6):503–8. https://doi.org/10.3109/21681805.2013.788552.

    Article  CAS  PubMed  Google Scholar 

  58. Wang J, Wang Q, Wu Q, Chen Y, Wu P. Intravesical botulinum toxin a injections for bladder pain syndrome/interstitial cystitis: a systematic review and meta-analysis of controlled studies. Med Sci Monit. 2016;22:3257–67. https://doi.org/10.12659/msm.897350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Barua JM, Arance I, Angulo JC, Riedl CR. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2016;27(8):1137–47. https://doi.org/10.1007/s00192-015-2890-7.

    Article  PubMed  Google Scholar 

  60. Dawson TE, Jamison J (2007) Intravesical treatments for painful bladder syndrome/interstitial cystitis. Cochrane Database Syst Rev (4):CD006113. https://doi.org/10.1002/14651858.CD006113.pub2.

Download references

Acknowledgements

This study was funded by 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant Nos. ZY2016104) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant Nos. ZYGD18011), and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant Nos. ZYGC18015). Project of Science and Technology Department of Sichuan Province (2018SZ0177, 2018SZ0055).

Author information

Author notes

  1. Xing-peng Di and De-yi Luo contributed equally to this work

Authors and Affiliations

  1. Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People’s Republic of China

    Xing-peng Di, De-yi Luo, Xi Jin, Hong Li & Kun-jie Wang

  2. Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China

    Wan-yu Zhao

Authors
  1. Xing-peng Di
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. De-yi Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xi Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wan-yu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kun-jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kun-jie Wang.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di, Xp., Luo, Dy., Jin, X. et al. Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis. Int Urogynecol J 32, 1129–1141 (2021). https://doi.org/10.1007/s00192-020-04659-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-020-04659-w

Keywords

Search

Navigation